Am J Pathol

1. MOLINA-ALVAREZ A, Sanchez-Gonzalez B, Colomo L, Yelamos J, et al
   PARP-1 and PARP-2 in B-cell Lymphoma: Pathogenic Roles and Therapeutic Implications.
   Am J Pathol. 2025 Jul 24:S0002-9440(25)00248.
   

   >> Share

   
   

   
   Blood

2. SAM J, Leclercq-Cohen G, Gebhardt S, Surowka M, et al
   Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
   Blood. 2025 Aug 1:blood.2025028863. doi: 10.1182/blood.2025028863.
   

   >> Share

   
   

   
   Br J Haematol

3. CARPIO C, de la Cruz-Vicente F, Garcia-Sanz R, Zeberio I, et al
   A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.
   Br J Haematol. 2025 Jul 25. doi: 10.1111/bjh.70028.
   

   >> Share

   
   

   
   Cancer Res

4. MANARA P, Newsam AD, Venkatarame Gowda Saralamma V, Cunningham TA, et al
   Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy.
   Cancer Res. 2025 Jul 31. doi: 10.1158/0008-5472.CAN-24-3420.
   

   >> Share

   
   

   
   Eur J Haematol

5. FUGLKJAER AD, Kilic DK, Eskesen MH, Simonsen MR, et al
   Machine Learning for Prediction of High-Risk Hospitalizations in Lymphoma Patients: A Danish Population-Based Study.
   Eur J Haematol. 2025 Jul 29. doi: 10.1111/ejh.70012.
   

   >> Share

   
   

   
   J Clin Oncol

6. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
   Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
   J Clin Oncol. 2025 Jul 29:JCO2501700. doi: 10.1200/JCO-25-01700.
   

   >> Share

   
   
7. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
   Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
   J Clin Oncol. 2025;43:2461-2466.
   

   >> Share

   
   

   
   Leuk Lymphoma

8. FUJINO T, Okamoto H, Nishiyama D, Hayata H, et al
   Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.
   Leuk Lymphoma. 2025;66:1425-1436.
   

   >> Share

   
   

   
   Leukemia

9. HEAVICAN-FORAL TB, Korell F, Scarfo I, Wiggers CRM, et al
   Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.
   Leukemia. 2025 Jul 30. doi: 10.1038/s41375-025-02697.
   

   >> Share

   
   
10. BERG V, Lollies A, Schneider M, Johansson P, et al
    Common origin and somatic mutation patterns of composite lymphomas and leukemias.
    Leukemia. 2025;39:1960-1971.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

11. HUANG Y, Lin H, Shi J, Chen Y, et al
    Serum metabolic patterns reveal the diagnostic and prognostic role of alanine abnormality in ocular adnexal lymphoma.
    Proc Natl Acad Sci U S A. 2025;122:e2506345122.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share